GeoVax Labs, an Atlanta-based biotechnology company, today announced a major milestone in its quest to eliminate the HIV virus, as the first patient has been inoculated with the company's HIV/AIDS vaccine following success in post-vaccine viral control in primates.

The company's vaccine is aimed at stimulating the body's immune system to resist the spread of infection.

"Dosing the first study participant marks a major milestone for our Phase 1/2 clinical trial. We are pleased to have the AIDS Research Consortium of Atlanta, the Alabama Vaccine Research Center at the University of Alabama, Birmingham, and the AIDS Research Alliance of Los Angeles participating in the trial,” said Robert McNally, president and CEO of GeoVax Labs, in a prepared statement.

“These three trial sites are actively seeking persons who are interested in and fit the criteria for the study," McNally added.

HIV researcher moves forward with vaccine trial

GeoVax is currently enrolling participants in the clinical trial, which is being conducted at the AIDS Research Consortium of Atlanta, the company announced.

For more information on GeoVax and for information on signing up for its clinical trial, visit